## Supporting Information

## **Fluorinated DNA Micelles: Synthesis and Properties**

Jianmei Zou<sup>‡,1</sup>, Cheng Jin<sup>‡,1</sup>, Ruowen Wang<sup>‡,</sup>II, Hailan Kuai<sup>‡</sup>, Lili Zhang<sup>‡</sup>, Xiaobing

Zhang‡, Juan Li<sup> $\alpha_{\parallel}^{\dagger}$ </sup>, Liping Qiu<sup>\*,‡,†</sup> Weihong Tan<sup>\*,‡,†</sup>

<sup>‡</sup>Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life sciences, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan, 410082, China

Institute of Molecular Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, College of Chemistry and Chemical Engineering, Shanghai, 200240, People's Republic of China

&MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry, Fuzhou University, Fuzhou 350116, P. R. China †Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at the Bio/Nano Interface, UF Health Cancer Center, UF Genetics Institute, McKnight Brain Institute, University of Florida, Gainesville, FL 32611-7200, USA

\* To whom correspondence should be addressed.

<sup>†</sup>Co-first authors.

E-mail: qiuliping\_0615@163.com, tan@chem.ufl.edu

Tel: +86-731-88821894

## **Table of Content**

Experimental section				
Figure S1. <sup>1</sup> H NMR spectrum of synthesized compound 1 S-3				
Figure S1. <sup>19</sup> F NMR spectrum of synthesized compound 1 S-4				
Figure S1. <sup>1</sup> H NMR spectrum of synthesized compound 2 S-4				
Figure S1. <sup>19</sup> F NMR spectrum of synthesized compound 2 S-5				
Figure S1. <sup>31</sup> P NMR spectrum of synthesized compound 1 S-5				
Figure S6. High-performance liquid chromatography profile of PF-T <sub>15</sub> -TAMRA				
Figure S7. ESI-MS analysis of PF-T <sub>15</sub> -TAMRA				
Figure S8. Dynamic light scattering data				
Figure S9. Comparison of target binding affinity between PFDM and free DNA				
Figure S10. Cell viability of compound 2 and PFDMS-7				
Table S1. DNA sequences designed in this work				
Table S2. The elution program for HPLC purification of lipid-conjugated				
oligonucleotides				

## **Experimental section**

**Materials.** 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11 Heptadecafluorodecyl iodide and 2-cyanoethyl-N, N-diisopropylchlorophosphoramidite were purchased from Sigma. N,N-Diisopropylethylamine (DIPEA), 4-aminophenol, Dimethylformamide (DMF), Ethyl acetate (EtOAc), hexanes, Na<sub>2</sub>SO<sub>4</sub>, NaHCO<sub>3</sub>, doxorubicin (DOX) and other chemical regents were obtained from commercial suppliers. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was purchased from Promega. Ultrapure Milli-Q water (Millipore) was used throughout the experiments.

**Synthesis** of compound 1. 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11 Heptadecafluorodecyl iodide (1 g, 1.7 mmol), DIPEA (0.22 g, 1.7 mmol) and 4-aminophenol (0.083 g, 0.77 mmol) were mixed in anhydrous DMF solution (5 mL) under nitrogen gas protection and stirred in reflux at 120 °C overnight. Upon cooling to room temperature, the reaction mixture was poured into 50 mL of water and then extracted 3 times with 100 mL EtOAc. The collected organic compound was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under low pressure. After purification by flash chromatographic column (hexanes to 20/80 EtOAc/hexanes), compound 1 of ~0.5g was obtained and identified by <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.87 (s, 1H), 6.85 (d, 2H), 6.76 (d, 2H), 3.28 (t, 4H), 2.33 (m, 4H), 1.80 (m, 4H) and <sup>19</sup>F NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  -82.30 (t, 6F), -115.17 (s, 4F), -122.65-123.2 (m, 12F), -123.91 (s, 4F), -124.74 (s, 4F), -127.42(s, 4F).



**Figure S1.** <sup>1</sup>H NMR spectrum of compound 1.



**Figure S2.** <sup>19</sup>F NMR spectrum of compound 1.



**Figure S3.** <sup>1</sup>H NMR spectrum of compound 2.



Figure S4. <sup>19</sup>F NMR spectrum of compound 2.



**Figure S5.** <sup>31</sup>P NMR spectrum of compound 2.



**Figure S6.** High-performance liquid chromatography (HPLC) profile of PF-T<sub>15</sub>-TAMRA. The retention time of  $\sim$ 32 min represents PF-T<sub>15</sub>-TAMRA, and the retention time of  $\sim$ 12 min represents unconjugated DNA fragments.



**Figure S7.** ESI-MS analysis of the diperfluorodecyl-DNA conjugates (PF-DNA) with the sequence of PF-TTT TTT TTT TTT TTT-TAMRA. The calculated molecular weight of the PF-DNA and the DNA fragment was 6215.9 g/moL and 6218.2 g/moL, respectively.

![](_page_6_Figure_2.jpeg)

Figure S8. Dynamic light scattering (DLS) data of 2  $\mu$ M PF-T<sub>30</sub> (A) and 2  $\mu$ M PF-T<sub>45</sub> (B) in DPBS plus 5 mM Mg<sup>2+</sup>.

![](_page_7_Figure_0.jpeg)

**Figure S9.** Comparison of target binding affinity between PF-DNA micelles (PFDM) and free DNA. Fluorescence intensity of FAM-labelled PFDM and FAM-labelled DNA with addition of Dabcyl-labelled cDNA at different concentrations.

![](_page_7_Figure_2.jpeg)

**Figure S10.** Cytotoxicity of compound 2 and PF-DNA conjugate. Cells (3T3-L1, CEM and HeLa) were incubated with compound 2 or PF-DNA conjugate of different concentrations at 37 °C for 48 h, and the cell viability was tested with a MTS assay.

 Table S1. DNA sequences designed in this work.

Name	Sequences (from 5' to 3')		
PF-py-T <sub>15</sub>	PF-py-TTT TTT TTT TTT		
PF-py-T <sub>30</sub>	PF-py-TTT TTT TTT TTT TTT TTT TTT TTT TTT TT		
PF-py-T <sub>45</sub>	PF-py-TTT TTT TTT TTT TTT TTT TTT TTT TTT TT		
<b>py-T</b> <sub>15</sub>	py-TTT TTT TTT TTT TTT		
PF-DNA-FAM	PF-TTT CCC AGC CCT C-FAM		
DNA-FAM	CCC AGC CCT C-FAM		
cDNA-Dabcyl	Dabcyl-GAG GGC TGG G		
<b>PF-T</b> <sub>15</sub>	PF- TTT TTT TTT TTT TTT		
T <sub>15</sub>	TTT TTT TTT TTT TTT		
PF-T <sub>15</sub> -TAMRA	PF- TTT TTT TTT TTT-TAMRA		
T <sub>15</sub> -TAMRA	TTT TTT TTT TTT TTT-TAMRA		
cDNA-BHQ	BHQ-AAA AAA AAA AAA AAA		

Notes: PF indicates diperfluorodecyl chain modification; py indicates pyrene molecule.

Time/min	A (0.1M TEAA)	B (acetonitrile)
0	95%	5%
4	95%	5%
4.01	90%	10%
40	10%	90%
50	10%	90%

**Table S2.** HPLC purification of lipid-conjugated oligonucleotides according to this elution program.